MilliporeSigma Relaunches Customer Collaboration Centers with New Concept and M Lab™ Name
- State-of-the-art laboratories for full end-to-end process development support and training
- Enables explorations of new technologies and solutions to address development and manufacturing challenges
- Dynamic settings in major pharmaceutical and biotechnology hubs promote customer collaboration from pre-clinical through full-scale production
Billerica, Massachusetts, July 18, 2016 — MilliporeSigma today is relaunching its global network of customer collaboration centers, providing customers a shared, exploratory environment with scientists and engineers working to solve their toughest biomanufacturing challenges and helping accelerate development of new therapies.
Formerly known as biomanufacturing science training centers, the new state-of-the art M Lab™ Collaboration Centers provide a simulated manufacturing environment for experiments, troubleshooting and problem solving, in a non-GMP setting, that fosters education and full end-to-end process development support. Customers participate in product demonstrations, hands-on training and proof-of-concept work, as well as apply best practices and new approaches to develop, optimize and scale-up processes and simplify global technology transfer.
"These centers have been an important resource for our customers and the biopharma industry for more than two decades," said Udit Batra, Member, Executive Board, Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma. "Now reimagined and reengineered as M Lab™ Collaboration Centers, we have taken our industry-leading concept to the next level. We are creating unique and inspiring settings where customers can explore new ways to increase productivity and improve processes in close collaboration with our team of experts."
MilliporeSigma unveiled its first remodeled center in Tokyo, Japan on June 29, 2016. The network, established in 1995, will also include locations in Brazil, China, France, India, Singapore, South Korea and the United States with formal relaunch of centers around the world taking place throughout the remainder of 2016 and 2017.
Each M Lab™ Collaboration Center will welcome customers and collaboration partners from government, academia, regulatory bodies and industry associations, offering application best practices and knowledge sharing tailored to address the specific needs of local pharmaceutical manufacturers. Customers will have access to sizing and simulation tools and methodologies as well as analytical and modeling support and customer education programs.
To learn more about the M Lab™ Collaboration Centers and view videos of MilliporeSigma’s facilities, visit www.emdmillipore.com/mlab.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA, Darmstadt, Germany will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting.